


# The German Asthma Net: Patients without any T2 biomarker signal are exceedingly rare

C. Bal, S. Zehetmayer, S. Stoshikj, K. Milger, D. Skowasch, C.Schulz, M. Jandl, O. Schmidt, R. Ehmann, C. Taube, E. Hamelmann, R. Buhl, S. Korn, M. Idzko.




CB, SS and MI Department of Pneumology, University Hospital Vienna AKH, Medical University of Vienna, Vienna, Austria, KM Department of Medicine V, Ludwig-Maximilians-University (LMU) of Munich; Comprehensive Pneumology Center (CPC-M) German Center for Lung Research (DZL), Munich, Germany, DS Department of Internal Medicine II - Pneumology, University Hospital Bonn, Bonn, Germany, CS Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany, MJ Hamburger Institut für Therapieforschung GmbH, Hamburg, Germany, OS Pneumologische Gemeinschaftspraxis und Studienzentrum KPPK, Koblenz, Germany, RE Ambulante Pneumologie mit Allergiezentrum, Stuttgart, Germany, SZ Section for Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria, CT Department of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Essen, Germany, EH Kinderzentrum Bethel, Evangelisches Klinikum Bethel, University Bielefeld, Bielefeld, Germany, RB Mainz University Hospital, Pulmonary Department, Mainz, Germany, SK Thoraxklinik Heidelberg und IKF Pneumologie Mainz, Mainz, Germany.

**Acknowledgements: The German Asthma Net is supported by scientific grants from AstraZeneca, Chiesi, GSK, Sanofi.** None of the supporting parties had any participation in the data, nor did they contribute to the design or the content of the present poster.

## Introduction

Severe asthma is a type 2 inflammation (T2) driven disease, in clinical practice measured by fraction of exhaled nitric oxide (FeNO), blood eosinophil counts (BEC), and allergy-triggered symptoms. However, clinical studies also show a **type-2-low (NT2) endotype of unclear relevance.**



Who are the **severe asthma** patients with **no type 2** signal?

**Methods:** This longitudinal study assesses Non-type 2 (NT2) in the **German Asthma Net (GAN)**, an international, multi-centre, real-life severe asthma registry through Kruskal-Wallis and Chi<sup>2</sup> tests.

**NT2 = ERS/ATS- and ERS task-force-defined:**

- ✓ FeNO < 40 ppb
- ✓ BEC < 300/μL
- ✓ no allergic or mixed asthma phenotype
- ✓ in patients without OCS

*No reduction of OCS/ICS was performed to assess T2-status*

## Results

**n=49**  
Systemic corticosteroid dependent

**The 40 NT2 patients had less total IgE (p=0.001), higher age (p=0.012), and more LAMA use (76% vs 58%, p=0.035).**

**Similar lung function, asthma control, quality of life, chronic rhinosinusitis, and reflux (p>0.05).**

**n=21**  
Historical T2 values

- **n=14** started targeted treatment
  - 46% high FeNO
  - 69% high BEC

**n=19**  
NT2

**Conclusion: 40 of 2064 severe asthma patients had no current T2 signature, with more than half presenting T2 markers at other time points.**